Half-Year 2022 Financial and Clinical Trials Update slide image

Half-Year 2022 Financial and Clinical Trials Update

Tecentriq Anti-PD-L1 cancer immunotherapy - breast cancer Indication Phase/study # of patients Design Phase III IMpassion 130 N=902 ARM A: Tecentriq plus nab-paclitaxel ARM B: Placebo plus nab-paclitaxel Previously untreated metastatic triple negative breast cancer (TNBC) Phase III IMpassion 132 N=572 ARM A: Tecentriq plus capecitabine or carbo/gem ARM B: Placebo plus capecitabine or carbo/gem Primary endpoint Progression-free survival and overall survival (co-primary endpoint) ■ Study met co-primary endpoint of PFS in both PD-L1+ and ITT populations Q3 2018 ■ Overall survival FPI Q1 2018 " Primary PFS and interim OS data presented at ESMO 2018 and ASCO 2019 Data published in NEJM 2018; 379:2108-2121 Status US accelerated approval Q1 2019 - US indication voluntarily withdrawn Q3 2021 CT Identifier ■ Approved in EU Q3 2019 Final OS presented at ESMO Asia 2020 NCT02425891 NCT03371017 Carbo/gem-gemcitabine and carboplatin; ITT-Intention to treat; PD-L1-Programmed cell death-ligand 1; PFS-Progression-free survival; OS-Overall survival; ESMO-European Society for Medical Oncology; ASCO=American Society of Clinical Oncology; NEJM=New England Journal of Medicine Roche 24 94 Oncology
View entire presentation